As new, innovative therapies with high price tags, such as chimeric antigen receptor (CAR) T-cell therapy, come to market, the US health system will have to start looking at different approaches for reimbursement, said Ted Okon, MBA, executive director of the Community Oncology Alliance.
As new, innovative therapies with high price tags, such as chimeric antigen receptor (CAR) T-cell therapy, come to market, the US health system will have to start looking at different approaches for reimbursement, said Ted Okon, MBA, executive director of the Community Oncology Alliance.
Transcript
How would you like to see CAR T and other innovative, but expensive, therapies reimbursed?
At the Community Oncology Conference, the keynote speaker, Dr Scott Gottlieb, the FDA commissioner, voiced concern about how these new technologies, specifically CAR T, will be reimbursed and expressed great concern about that. And we share that concern too. This is not your normal drug, this is more of an overall therapy and I think that we have to look at different, new ways of reimbursing it.
I think we also have to look at the cost of these therapies, which I know why Dr Gottlieb is looking at speeding at the approvals of not only generics and biosimilars but new brands, so you introduce competition into the market. When you have competition, you will bring down prices. That will, in part, handle some of the reimbursement problem, but I think we really have to look at a different approach to reimbursement of these very expensive therapies.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen